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Abstract The proteolytic fragments derived from the amyloid 
precursor protein (APP) in primary cultures of rat hippocampal 
neurons were analyzed by two-dimensional gel electrophoresis. 
The Semliki Forest Virus expression vector was used to express 
human APP695 and a mutant form associated with familial Alz- 
heimer's disease (APP-FAD670/671). Hippocampal neurons ex- 
pressing wtAPP695 or APP-FAD6701671 secrete at least six 
APP fragments of 100-110 kDa with isoelectric focusing points 
ranging from 4.5 to 4.0. The heterogeneity of the secreted APP 
forms is shown to be in part due to differences in glycosylation. 
In contrast to wtAPP695, neurons producing the APP-FAD6701 
671 variant did not secrete detectable amounts of secretory APP 
derived from cleavage within the amyloid /3A4 domain. This 
result suggests that there is little a-secretase cleavage in neurons 
expressing the APP-FAD6701671 mutant. 
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1. Introduction 
The amyloid precursor protein (APP), a widely expressed 
membrane-spanning glycoprotein, is the precursor of a series 
of soluble proteins and peptides, including the flA4 amyloid 
peptide [1]. Several lines of evidence suggest hat this flA4 
peptide is involved in the pathogenesis of Alzheimer disease 
(AD). First, the flA4 peptide is the principal component of 
extracellular amyloid depositions in the form of plaques and 
vascular amyloid in the brains patients with AD [2,3]. Second, 
several missense mutations which occur within or immediately 
bordering to the flA4 region of the APP gene are linked to early 
forms of AD [4]. Third, transgenic mice overexpressing human 
APP/FAD 717 show the AD associated neuropathology [5]. 
APP is proteolytically cleaved by a putative ~-secretase 
within the region spanned by the flA4 peptide to generate a
large soluble ectodomain which is secreted [6,7]. This cleavage 
occurs with mature N and O glycosylated APP, probably dur- 
ing transport from the Golgi complex to the cell surface [8,9] 
and at the plasma membrane [10,11]. Alternatively, APP can 
be proteolytically processed within endosomes and lysosomes 
after internalisation f the holo-protein from the cell surface to 
produce the flA4 peptide [10,12]. 
Although pathological manifestations of AD such as plaque 
and vascular amyloid formation, neurofibrillary tangles and 
neuronal dysfunction occur in the central nervous ystem, APP 
metabolism has mainly been studied in non-neuronal cells. The 
available information of APP expression and metabolism in 
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neuronal cells, however, suggest hat differences exist. First, 
neurons express high amounts of an APP isoform (APP695), 
while longer APPs (751 and 770) containing a Kunitz Protease 
Inhibitor (KPI) insert and those lacking exon 15 (L-APPs) are 
more abundant in peripheral tissue [13,14]. Second, neurons 
have an intrinsic tendency to catabolise APP in an amy- 
loidogenic fashion, because high amounts of flA4 and flA4 
containing carboxyl-terminal remnants are produced [15]. 
Third, APP follows a complicated intracellular pathway in po- 
larized neurons being initially routed to the axon followed by 
transport to the dendrites most likely by a mechanism similar 
to transcytosis n epithelial cells [16,17]. 
In this study, we have expressed APP in primary cultures of 
rat hippocampal neurons. Hippocampal neurons are among the 
most vulnerable nerve cells in AD. Cultured hippocampal neu- 
rons have been studied extensively and display the characteris- 
tics of hippocampal neurons in situ [18]. They undergo a se- 
quence of differentiation steps that lead to maturation i to fully 
polarized neurons with axon and dendritis forming stable syn- 
aptic connectivities on the culture dish [19]. The difficulty to 
obtain sufficient amount of material for biochemical analysis 
was circumvented by using the Semliki Forest Virus (SFV) 
expression system [20]. The neurons were infected with recom- 
binant SFV containing human APP695 or APP/FAD670/671 
and the proteolytic fragments were analyzed by two-dimen- 
sional gel electrophoresis. 
2. Materials and methods 
2,1. Cell culture 
Hippocampal neuron cultures were prepared as described by Goslin 
and Banker [21]. Briefly, the hippocampi of 18-day-old rat embryos 
were dissected, trypsinized, and further dissociated by repeated pas- 
sages through a constricted Pasteur pipette. The cells were plated on 
poly-lysine coated plastic dishes (at a density of 4 × 10516 cm dish) and 
kept in minimum essential medium (MEM) supplemented with 10% 
horse-serum. After attachment, cells were maintained in 5.0% CO 2 at 
36.5°C in MEM with N 2 supplement ('maintenance m dium'). For all 
experiments, cells were cultured for 8 12 days in vitro before use. 
2.2. DNA constructs 
A Sma I site was used to isolate the complete coding region of the 
eDNA encoding the human APP695 and subcloned into pSP65. The 
eDNA coding for human APP695 was cloned as a HindIII fragment 
in the expression vector pSG5 (Stratagene). The APP K670N/M671L 
mutations were generated by site-directed mutagenesis in the pSG5 
plasmid. The construct was analyzed by restriction analysis and by 
sequencing of the mutated sites. A Spe I site in the non-coding region 
was removed by using Klenow fragment. APP695 and APP K670N/ 
M671L were subcloned into the Sma I site of pSFV1. 
2.3. Preparation of recombinant SFV 
pSFVI-APP695, pSFV-APP-FAD6701671 and pSFV1-Helperl were 
linerarized with Spe I, and run-off transcription was performed with 
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SP6 RNA polymerase. Each APP transcription mix was cotransfected 
with the Helper-transcription mix to BHK cells using electroporation 
as described by Olkkonen et al. [22]. The culture supernatant was 
collected after 20-24 h incubation (5% CO2, 37°C). Titration of the viral 
stocks were performed as described by Olkkonen et al. [22]. 
2.4. Injection of neurons, metabolic labelling, enzymatic deglycosylation 
and immunopreeipitation 
Recombinant SFV diluted in maintenance medium was allowed to 
adsorb to the ceils for 1 h at 36.5°C in 5% CO2. The virus solution was 
replaced by maintenance medium and the infection continued for 2 to 
3 h. The medium was exchanged by methionine free N 2 medium and 
metabolic labelling performed for 3 h with 200-300 /zCi/ml [35S] 
methionine. After metabolic labelling extracellular medium was har- 
vested and cells extracts prepared in 1% Triton X-100, 1% sodium de- 
oxycholate and 0.1% SDS with 10/zg/ml chymostatin, leupeptin, anti- 
pain and pepstatin. 
Immunoprecipitations were performed with 3/tl of goat antiserum 
R217 against soluble APP [23], 10 ~1 of anti-Fd APP [6], 10/11 of Ab692 
prepared against synthetic flA4 peptide, or 20/zl of B13 prepared 
against synthetic flA4 (1 16). Immune complexes were recovered with 
protein A-Sepharose (Pharmacia Biotech Inc.) or protein G-agarose 
(Immunopure, Pierce). Processing of immune complexes was as de- 
scribed previously [15]. For digestion with neuraminidase (Boehringer 
Mannheim), immunoprecipitates w re made 1% SDS and 1% fl-mer- 
captoethanol, boiled for 5 min and diluted 10-fold to final concentra- 
tions of 50 mM of sodium acetate and 4 mM calcium chloride (pH 5.5), 
1% NP-40, 0.1% SDS, 10 pg/ml chymostatin, leupeptin, antipain, pep- 
statin and 2 U/ml neuraminidase. After incubation at 37°C for 16 h, 
samples were analyzed by two-dimensional ge electrophoresis. 
2.5. Two-dimensional gel electrophoresis 
A combination of isoelectric focusing (IEF) and SDS-PAGE was 
used to resolve proteins in two dimensions essentially as described 
previously [24]. For IEF samples were solubilized in 9.8 M urea, 4% 
(w/v) NP-40, 2% (v/v) ampholines, pH 7-9 (Pharmacia LKB, Bromma, 
Sweden), and 100 mM DTT. Two volumes of Ampholine pH 3.5-5.0 
(Sigma) and one volume of Ampholine pH 3.5-10.0 were (Pharmacia 
LKB) used for the first dimension. IEF gels were run at 500 V for 10 
rain and 750 V for 3.5 h. For the second imension 7.5%, 10% and 20% 
SDS-PAGE were used. 
3. Results and discussion 
The SFV expression system has several features which make 
it a suitable xpression system for studying APP metabolism in
primary neuronal cultures. The SFV vector infects neurons 
efficiently and expresses the heterologous proteins within a few 
hours. The virus shuts off host cell protein synthesis and pro- 
duces APP in relatively high amounts without disturbing the 
polarized organization and viability of the cells during the early 
phase of infection [15,16,22]. 
A dish of 4 x 10 ~ neurons was infected by recombinant SFV 
carrying human APP695 and metabolic labelling was per- 
formed during 3 h. Cell homogenate was immunoprecipitated 
by anti-Fd APP and analyzed by two-dimensional gel electro- 
phoresis. As shown in Fig. 1A the cellular APP forms migrated 
at the same apparent molecular weight of I00 kDa and at pls 
ranging from 4.2 to 4.8 (theoretical Ip 4.6). The wide range of 
APPs isoelectric points is most likely due to different post- 
translational modifications. 
To analyze the secreted forms of APE culture medium from 
hippocampal neurons was immmunoprecipitated with either 
anti-Fd APP or R217. Both antibodies revealed a similar pat- 
tern on two-dimensional gelelectrophoresis (Fig. 1C). Secreted 
APP695 appeared at least 6 separate spots (indicated from a-f, 
see Fig. 2B) with molecular weights between 100 and 110 kDa and 
isoelectric points ranging from 4.0 to 4.5 (theoretical Ip 4.5). 
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Fig. 1. Two-dimensional gemapping of APP695 from cell-homogenate 
and culture medium of rat hippocampal neurons. Two-dimensional 
images resulted from APP immunoprecipitated from cell-homogenate 
(A) and from culture medium (C) of SFV/APP695 infected hippocam- 
pal neurons. Alternatively, culture medium was TCA precipitated and 
directly applied on two-dimensional gels (B). 
Because the SFV vector efficiently produces APE it is the 
main protein being secreted under these conditions. Culture 
medium can therefore directly be processed for two-dimen- 
sional gel electrophoresis without being immunoprecipitated as 
demonstrated in Fig. lB. 
To analyze the heterogeneity of secreted APP695, im- 
munoprecipitated culture media was digested with carbohy- 
drate cleaving enzymes. Treatment with neuraminidase resulted 
in the disappearance of the three most acidic spots (spots c, e 
and f) (Fig. 2C,D). The result demonstrates that secretory 
APP695 heterogeneity s partially due to different amounts of 
sialyl-residues in APP. To investigate if different proteolytical 
cleavages could be responsible for the three remaining spots on 
two-dimensional electrophoresis, culture media was im- 
munoprecipitated with an antibody (B13) raised against syn- 
thetic flA4 1-16 peptide, and thus specific for a-cleaved frag- 
ments. B 13 immunoprecipitates w re compared to anti-Fd APP 
immunoprecipitates, which precipitate all secreted forms. As 
shown in Fig. 3A,B, no major difference were observed, indicat- 
ing that all spots contained the flA4 1 16 peptide carboxyl- 
terminally. 
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Fig. 2. Characterization f secreted APP. APP695 was immunoprecip- 
itated from culture medium of rat hippocampal neurons infected with 
SFV/APP695 and enzymatically digested with neuraminidase (C). The 
control sample is shown in (A). Experiment is schematically summa- 
rized in (B) and (D), respectively. 
Finally, we completed the two-dimensional gel mapping of 
secretory fragments derived from APP695 by analyzing the low 
molecular weight peptides in the culture medium of neurons. 
We have previously shown, that hippocampal neurons express- 
ing human APP695, mainly secrete flA4 among the low molec- 
ular weight peptides [15]. Two dishes of 4 x 105 neurons were 
infected with SFV/APP695 and metabolically abelled during 
8 h. Culture medium was pooled and immunoprecipitated with 
Ab692. The resulting two-dimensional gel pattern demon- 
strates that flA4 is efficiently produced (Fig. 4). 
We extended the mapping of secretory APP to a clinical 
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mutant associated with AD. The double mutation 670/671 was 
introduced into human APP695, cloned into the SFV vector 
and high titer viral stocks were prepared. 
Secreted APP was analyzed by immunoprecipitation with 
anti-Fd APP and Ab BI3. Anti-Fd APP revealed a similar 
pattern as already observed for wtAPP695 (Fig. 3A,C). While 
B13 clearly precipitates secreted APP from culture media of 
SFV/wtAPP695 infected neurons (Fig. 3B), no secreted APP 
could be detected from SFV/APP-FAD6701671 infected neu- 
rons. This result indicates that the APP carrying the 670/671 
double mutation does not secrete any detectable s-secreted 
fragments in hippocampal neurons, but secrete instead a trun- 
cated APP lacking the flA4 1-16 region. 
Two-dimensional PAGE is a convenient method to study 
APP metabolism in neurons. It is well suited for dealing with 
the complexity of APP derived proteolytic fragments. Due to 
efficient protein expression by the SFV vector, culture medium 
can directly be analyzed on two-dimensional gels without he 
use of any antibodies. Analysis of secreted APP reveals that 
neuronal APP is heterogeneous. This can not be appreciated on 
conventional SDS-PAGE. Secretory neuronal APP is resolved 
into at least 6 spots with a molecular weight between 100 and 
110 kDa and an isoelectricfocusing point ranging from 4.0 to 
4.5 on two-dimensional gel electrophoresis. The wide isoelec- 
tricfocusing range is mainly due to different amounts of sialyl- 
residues in secreted APE 
The characterized APP spots can now be used as a reference 
map to identify APP fragments in the context of neuronal cells, 
tissues, or subcellular f actions of patients and controls. 
The most dramatic result of this study was the comparison 
of secreted APP from SFV infected hippocampal neurons ex- 
pressing wild-type or FAD 670/671 APP. Secreted APP con- 
taining flA4 1-16, and thus most likely a result of s-cleavage, 
was readily detected in neurons expressing wtAPP695, but was 
virtually absent from neuronal cultures expressing APP- 
FAD670/671. This result suggests that hippocampal neurons 
containing APP-FAD670/671 do not secrete any appreciable 
amounts of c~-cleaved APP, but secrete mainly a shorter APP 
form. We do not know why this mutant escapes -cleavage in 
neurons. One possible explanation would be that proteolytic 
cleavage responsible for secretion of APP in case of the FAD- 
Fig. 3. Comparison of secreted APP from hippocampal neurons expressing APP695 (A,B) or APP-FAD670/671 IC,D). Culture medium was 
immunoprecipitated with anti-Fd APP (A,C) or B13 raised against syntheticflA4 1 16 (B,D). While B 13 clearly immunoprecipitates APP from culture 
medium of cells infected with SFV/APP695, it does not recognize any APP in culture medium of cells infected with SFV/APP-FAD670/671. 
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Fig. 4. flA4 secretion of hippocampal neurons infected with SFV/ 
APP695. Culture medium was immunoprecipitated with Ab692 and 
separated with two-dimensional gelelectrophoresis. 
670/671 mutant occurs before a-secretase cleavage in the bio- 
synthetic pathway. An altered intracellular routing of the APP 
mutant leading to transport o different processing compart- 
ments must also be considered. The double mutation 670/671 
could also directly inhibit a-cleavage and thus favour fl-cleav- 
age. However, this is unlikely because the mutations are located 
proximally to the fl-cleavage site [25]. 
Several cell-lines have been transfected with constructs con- 
taining the double mutation 670/671 and increased amounts of 
flA4 have been detected [26,27]. The increase of flA4 produc- 
tion has so far not been associated with changes in APP secre- 
tion. This study now demonstrates that increased amounts of 
flA4 production is accompanied by the secretion of APP forms 
not containing the carboxyl-terminal region resulting from ~- 
secretase cleavage. This suggests that in case of FAD670/671, 
flA4 production starts before the mutant protein has reached 
the cell surface and is not simply a degradative process of 
full-length APP in endosomes/lysosomes. 
Neurons are not only the cells mostly affected during the 
pathogenesis of AD, but also a prominent source offlA4, there- 
fore it will be important in the future to study mechanism of 
flA4 production from mutant APP and wtAPP in these cells. 
The experimental strategies used in this study will be useful for 
pursuing these goals. 
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